{"relation": [["", "Arm 1. PEG +RBV for 48 Wks (Part I)", "Arm 2. PEG + RBV + BOC for 28 Wks (Part I)", "Arm 3. PEG + RBV + BOC (From Wk 4) for 24 Wks (Part I)", "Arm 4. PEG +RBV + BOC for 48 Wks (Part I)", "Arm 5. PEG + RBV+ BOC (From Wk 4) for 44 Wks (Part I)", "Arm 6. PEG + RBV + BOC for 48 Wks (Part II)", "Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)"], ["Description", "PegIntron (1.5 \u03bcg/kg QW) plus ribavirin (800 to 1400 mg/day) for 48 weeks. \u2022 Participants with detectable HCV-RNA levels after 24 weeks of treatment had to receive 24 weeks of PegIntron, ribavirin and boceprevir (800 mg TID) for 24 additional weeks. Total treatment duration was up to 54 weeks.", "Boceprevir (800 mg TID) plus PegIntron (1.5 \u03bcg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.", "PegIntron (1.5 \u03bcg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks lead in followed by boceprevir (800 mg TID) plus PegIntron (1.5 \u03bcg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.", "Boceprevir (800 mg TID) plus PegIntron (1.5 \u03bcg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.", "PegIntron (1.5 \u03bcg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks lead in followed by boceprevir (800 mg TID) plus PegIntron (1.5 \u03bcg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.", "PegIntron (1.5 \u03bcg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks.", "PegIntron (1.5 \u03bcg/kg QW), ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks."]], "pageTitle": "Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00423670?sect=X0125&view=results", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 61, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042982502.13/warc/CC-MAIN-20150728002302-00159-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 843833363, "recordOffset": 843815797, "tableOrientation": "HORIZONTAL", "TableContextTimeStampAfterTable": "{30816=PegIntron (1.5 \u03bcg/kg QW) plus ribavirin (800 to 1400 mg/day) for 48 weeks., 4141=PegIntron (1.5 \u03bcg/kg, once weekly [QW]) plus ribavirin (800 to 1400 mg/day) for 48 weeks.}", "textBeforeTable": "Reporting Groups Participants in Arm 1 (Part I) who had detectable Hepatitis C Virus-ribonucleic acid (HCV-RNA) at Treatment Week (TW) 24 were offered boceprevir in addition to PegIntron and ribavirin for an additional 24 weeks of treatment, and switched to a new arm, Arm 8. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details 765 participants were screened in the study, 598 were randomized of which 3 participants were not treated (Arm 1-7). Participants were assigned to Part I (with standard dosing for ribavirin) or Part II (to explore low-dose ribavirin). All participants that completed or discontinued treatment were scheduled to enter follow-up phase per protocol. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: boceprevir", "textAfterTable": "Arm 8. PEG + RBV + BOC (From Wk 24) for 48 Wks (Part I) Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with PegIntron (1.5 \u03bcg/kg QW), ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive 24 weeks of PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks. Participant Flow for 2 periods Period 1: \u00a0 Treatment Period \u00a0 \u00a0 Arm 1. PEG +RBV for 48 Wks (Part I) \u00a0 \u00a0 Arm 2. PEG + RBV + BOC for 28 Wks (Part I) \u00a0 \u00a0 Arm 3. PEG + RBV + BOC (From Wk 4) for 24 Wks (Part I) \u00a0 \u00a0 Arm 4. PEG +RBV + BOC for 48 Wks (Part I) \u00a0 \u00a0 Arm 5. PEG + RBV + BOC (From Wk 4) for 44 Wks (Part I) \u00a0 \u00a0 Arm 6. PEG + RBV + BOC for 48 Wks (Part II)", "hasKeyColumn": false, "keyColumnIndex": -1, "headerRowIndex": 0}